Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Total revenue $ 129 $ 101
Costs of revenue 80 61
Gross profit 49 40
Operating expenses:    
Research and development 1,653 1,595
General and administrative 856 1,000
Sales and marketing 394 286
Grant expenses 26
Total operating expenses 2,929 2,881
Loss from operations (2,880) (2,841)
Other income (expenses):    
Interest income 2 47
Change in fair value of derivative liabilities 41 (242)
Interest expense (8)
Forgiveness of PPP loan 391
Other income (net) 12
Total other income, net 35 208
Net loss before income taxes (2,845) (2,633)
Provision for income taxes
Net loss (2,845) (2,633)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on preferred stock
Net loss attributable to common stockholders $ (2,845) $ (2,633)
Net loss per share – basic and diluted    
Basic – net loss $ (0.12) $ (0.11)
Basic - deemed dividend and accretion of a discount on conversion of preferred stock
Basic – attributable to common stockholders (0.12) (0.11)
Diluted – loss (0.12) (0.11)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock
Diluted – attributable to common stockholders $ (0.12) $ (0.11)
Weighted average common shares outstanding:    
Basic 24,712,224 24,668,106
Diluted 24,712,224 24,668,106
Product [Member]    
Total revenue $ 101 $ 101
Grant [Member]    
Total revenue $ 28